Time‐varying brentuximab vedotin pharmacokinetics and weight‐based dosing in paediatric patients despite lower exposure in those aged 2 to
British Journal of Clinical Pharmacology · 2024
DOI: 10.1111/bcp.16128 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Daping Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Translational Clinical Sciences, Research and Development, Pfizer, Bothell, Washington, USA. Hauptthemen laut MEDLINE: Brentuximab Vedotin, Body Weight, Immunoconjugates. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Seagen Inc, which was acquired by Pfizer in December, 2023.
Abstract (Originalsprache)
Aims
We studied the pharmacokinetics and exposure–response relationships of the brentuximab vedotin (BV) antibody–drug conjugate (ADC) and unconjugated monomethyl auristatin E in haematologic malignancies.
Methods
This population pharmacokinetic analysis included data from five adult and three paediatric studies. Exposures in virtual adult and paediatric populations following BV 1.8 mg/kg (maximum 180 mg) intravenously every 3 weeks were simulated. Clinical endpoints included overall response rate, grade ≥2 peripheral neuropathy (PN) and grade ≥3 neutropenia.
Results
BV ADC exhibited linear pharmacokinetics, well‐described by a three‐compartment model, with body weight being the only significant covariate for exposure. Monomethyl auristatin E exhibited time‐varying formation rate. Simulated steady‐state BV ADC exposures in patients aged 12 to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Clinical Sciences, Research and Development, Pfizer, Bothell, Washington, USA.
- Clinical Pharmacology and Translational Sciences, Oncology Research and Development, Pfizer, Bothell, Washington, USA.
- Oncology Statistics, Oncology Research and Development, Pfizer, Bothell, Washington, USA.
- Oncology Research and Development, Pfizer, Bothell, Washington, USA.
- Clinical Pharmacology and Translational Sciences, Oncology Research and Development, Pfizer, South San Francisco, California, USA.
- Translational Clinical Sciences, Research and Development, Pfizer, South San Francisco, California, USA.
ORCID-Profile: Daping Zhang
Förderung
- Seagen Inc, which was acquired by Pfizer in December, 2023
Zitieren
APA
Zhang, D., Zhang, Z., Lee, A., Fenton, K., Jain, S., Garg, A., & Chia, Y. L. (2024). Time‐varying brentuximab vedotin pharmacokinetics and weight‐based dosing in paediatric patients despite lower exposure in those aged 2 to. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16128
Vancouver
Zhang D, Zhang Z, Lee A, Fenton K, Jain S, Garg A, et al. Time‐varying brentuximab vedotin pharmacokinetics and weight‐based dosing in paediatric patients despite lower exposure in those aged 2 to. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16128
BibTeX
@article{Zhang2024,
author = {Zhang, Daping and Zhang, Zufei and Lee, Anthony and Fenton, Keenan and Jain, Shweta and Garg, Amit and Chia, Yen Lin},
title = {Time‐varying brentuximab vedotin pharmacokinetics and weight‐based dosing in paediatric patients despite lower exposure in those aged 2 to},
journal = {British Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1111/bcp.16128}
}
EUVIMED